Ally Bridge Group NY LLC Invests $4.95 Million in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 309,614 shares of the company's stock, valued at approximately $4,951,000. Centessa Pharmaceuticals makes up 2.7% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 19th largest holding. Ally Bridge Group NY LLC owned about 0.27% of Centessa Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CNTA. Price T Rowe Associates Inc. MD lifted its position in shares of Centessa Pharmaceuticals by 16.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company's stock valued at $33,427,000 after acquiring an additional 418,615 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals during the first quarter worth $4,192,000. Lynx1 Capital Management LP purchased a new stake in Centessa Pharmaceuticals in the 1st quarter worth $197,000. HighMark Wealth Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $840,000. Finally, TD Asset Management Inc grew its position in shares of Centessa Pharmaceuticals by 40.5% during the second quarter. TD Asset Management Inc now owns 321,168 shares of the company's stock valued at $2,900,000 after purchasing an additional 92,524 shares in the last quarter. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Up 1.7 %

CNTA stock traded up $0.30 during trading on Thursday, hitting $17.60. 510,301 shares of the company's stock traded hands, compared to its average volume of 416,756. The firm has a market capitalization of $2.32 billion, a P/E ratio of -11.50 and a beta of 1.47. Centessa Pharmaceuticals plc has a 1 year low of $5.58 and a 1 year high of $18.74. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $12.57.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Ratings Changes

CNTA has been the topic of several recent research reports. Jefferies Financial Group upped their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. BMO Capital Markets increased their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley initiated coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price target on the stock. Finally, Oppenheimer restated an "outperform" rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $25.83.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now directly owns 206,750 shares of the company's stock, valued at $3,243,907.50. This represents a 7.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the transaction, the chief executive officer now owns 776,924 shares in the company, valued at $12,834,784.48. This represents a 18.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 375,128 shares of company stock valued at $6,148,522 in the last quarter. 11.59% of the stock is currently owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.